Tradestie Institutional Equity Comparison Engine
BGMSP vs CLRB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CLRB Overall Edge
CLRB Captures Institutional Edge (2โ1 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cellectar Biosciences INC NEW (CLRB) driven by superior Growth & Margin, Momentum & Technical while BGMSP counters with relative strength in Options & Structure. Fundamentally, BGMSP trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus CLRB at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, BGMSP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CLRB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
BGMSP N/M vs CLRB N/M Fwd P/E
Growth & Margin Winner
CLRB
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner
CLRB
1Y -72.6% vs -63.8% ยท 52W Pos 0% vs 0%
Options & Structure Winner
BGMSP
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
BGMSP
US Equity
BGMSP
Institutional Equity
$1.44
-39.75% 1D
Market Cap
N/A
1M Return
-60.98%
1Y Return
-72.57%
Forward P/E
N/M
Unified AI Score
42.7 / 100
HOLD
Tech 45.0
Fund 48.0
Flow 50.0
Mom 50.0
CLRB
NASDAQ
Cellectar Biosciences INC NEW
Pharmaceutical Preparations
$1.04
-8.77% 1D
Market Cap
$11.6M
1M Return
-8.77%
1Y Return
-63.76%
Forward P/E
N/M
Unified AI Score
39.4 / 100
SELL
Tech 25.0
Fund 49.0
Flow 44.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BGMSP -72.57%
CLRB -63.76%
Spread: +84.13 pp (CLRB Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
BGMSP TTM Op. Margin: N/A
CLRB TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGMSP vs CLRB. Trailing 12-month operating profitability (BGMSP N/A vs CLRB 0.0%) and valuation multiples (BGMSP N/M vs CLRB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BGMSP | CLRB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $11.6M | Larger Scale | CLRB |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +0.0% | Higher Growth | CLRB |
| Operating Margin (TTM) Profitability | N/A | 0.0% | Higher Margin | CLRB |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | CLRB |
| Return on Equity (ROE) Capital Efficiency | N/A | -162.6% | Higher ROE | CLRB |
| 52-Week Range Position Momentum | 0% ($1โ$14) | 0% ($1โ$5) | Stronger Trend | Tie |
| Beta / 30D Volatility Risk Regime | 0.59ฮฒ ยท 201% Vol | 1.28ฮฒ ยท 81% Vol | Lower Realized Risk | CLRB |
| Unified Institutional Score Composite Signal | 42.7 / 100 (HOLD) | 39.4 / 100 (SELL) | Higher Composite | BGMSP |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BGMSP vs CLRB Buy Guide
BGMSP
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CLRB
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BGMSP nor CLRB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.